Last reviewed · How we verify
S-1
S-1 is an oral combination of tegafur, gimeracil, and oteracil potassium that inhibits thymidylate synthase and enhances fluorouracil activity to suppress cancer cell DNA synthesis.
S-1 is an oral combination of tegafur, gimeracil, and oteracil potassium that inhibits thymidylate synthase and enhances fluorouracil activity to suppress cancer cell DNA synthesis. Used for Gastric cancer, Colorectal cancer, Pancreatic cancer.
At a glance
| Generic name | S-1 |
|---|---|
| Also known as | TS-1, Tegafur,Gimeracil and Oteracil Potassium Capsules, Oxaliplatin, Tegafur,, Tegafur Gimeracil Oteracil Potassium Capsule |
| Sponsor | TTY Biopharm |
| Drug class | Antimetabolite; fluoropyrimidine combination |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
S-1 combines three components: tegafur (a prodrug of fluorouracil), gimeracil (an inhibitor of dihydropyrimidine dehydrogenase that prolongs fluorouracil half-life), and oteracil potassium (which reduces gastrointestinal toxicity). Together, these enhance and stabilize fluorouracil-mediated inhibition of thymidylate synthase, a key enzyme in DNA synthesis, leading to cancer cell death.
Approved indications
- Gastric cancer
- Colorectal cancer
- Pancreatic cancer
- Biliary tract cancer
Common side effects
- Nausea and vomiting
- Diarrhea
- Anorexia
- Fatigue
- Bone marrow suppression (leukopenia, thrombocytopenia)
- Hand-foot syndrome
- Stomatitis
Key clinical trials
- Patient Satisfaction During Lomber Transforaminal Epidural Steroid Injection: The Role of Sedation, Anxiety, and Pain
- Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia (PHASE1)
- A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes (PHASE1)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) (PHASE2)
- Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia (PHASE1)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S-1 CI brief — competitive landscape report
- S-1 updates RSS · CI watch RSS
- TTY Biopharm portfolio CI